Will Medicare Cover Alzheimer’s Blood Tests? What South Carolina Families Should Know
Will Medicare Cover Alzheimer’s Blood Tests? What South Carolina Families Should Know
Key Takeaways
Blood tests may help doctors evaluate Alzheimer’s disease earlier, but they are not stand-alone diagnostic tests.
Current FDA-cleared testing is intended for certain adults who already show signs of cognitive decline—not routine screening of people without symptoms.
Medicare covers certain cognitive assessments and care-planning services, but it does not currently provide a general preventive screening benefit specifically for blood-based Alzheimer’s tests in people without symptoms.
Proposed federal legislation could create a Medicare coverage pathway for qualifying blood tests.
Earlier evaluations may provide more time for treatment discussions and legal, financial, caregiving, and long-term care planning.
Alzheimer’s disease can begin changing the brain years before memory loss and other symptoms become obvious. Researchers have developed blood tests that look for biological markers associated with those changes.
These tests could make an Alzheimer’s evaluation more accessible because a blood draw is generally less invasive and less expensive than a spinal tap or specialized brain scan. However, families should understand what these tests can—and cannot—tell them.
A blood test may indicate that additional evaluation is needed. It does not independently establish that someone has Alzheimer’s disease, determine how quickly symptoms will progress, or explain every possible cause of memory loss.
Who Should Consider an Alzheimer’s Blood Test?
Currently, blood testing is generally intended to help evaluate people who already have signs or symptoms of cognitive decline. Examples may include increasing memory problems, confusion, difficulty managing finances, trouble following familiar tasks, changes in judgment, or getting lost in familiar places.
These symptoms do not always mean a person has Alzheimer’s disease. Medication side effects, depression, sleep disorders, vitamin deficiencies, infections, thyroid problems, strokes, and other medical conditions may also affect memory and thinking.
A physician should evaluate the person’s symptoms, medical history, medications, age, and other test results before determining whether a blood test is appropriate. Current testing is not intended as a routine checkup for people without symptoms.
How Alzheimer’s Blood Testing Works
In 2025, the FDA cleared the Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio as the first blood test to aid in diagnosing Alzheimer’s disease. It is intended for adults age 55 and older who show signs or symptoms of cognitive decline and are being evaluated in a specialized care setting.
The test measures proteins in the blood associated with amyloid plaques in the brain. These plaques are a hallmark of Alzheimer’s disease, although their presence must be considered with other clinical information.
A positive result does not establish an Alzheimer’s diagnosis itself. A negative result may not rule out every cause of cognitive impairment. False positive, false negative, and unclear results are also possible.
Depending on the results, a physician may recommend cognitive testing, brain imaging, additional biomarker testing, a neurological examination, or a review of medications and medical history.
Does Medicare Cover Alzheimer’s Blood Tests?
Medicare does not currently provide a general preventive screening benefit specifically for blood-based Alzheimer’s tests in people without symptoms. Coverage for a blood test ordered as part of a diagnostic evaluation may depend on the test, medical necessity, the laboratory, and applicable Medicare rules. For patients who must pay out of pocket, Alzheimer’s blood tests can cost between $500 and $1,000, although exact prices and patient responsibility vary depending on the test, provider, and insurance coverage.
That could change under the proposed Alzheimer’s Screening and Prevention Act, also called the ASAP Act. The bill would amend Medicare law to create a pathway for coverage of qualifying FDA-cleared or approved blood-based dementia screening tests.
As of September 2026, the ASAP Act remains proposed legislation and has not become law. Even if enacted, a test would still need to satisfy Medicare’s coverage requirements. South Carolina patients should ask their health care provider and Medicare plan about coverage and expected costs before testing.
What Alzheimer’s-Related Services Does Medicare Cover?
Medicare Part B covers a separate cognitive assessment visit when applicable requirements are met. During this visit, a health care provider may:
Review memory, judgment, and other cognitive abilities
Examine medications and medical history
Speak with a caregiver or family member
Establish or confirm a diagnosis
Develop a plan to help address and manage symptoms
Discuss community resources and caregiver support
Discuss advance care planning
Refer the patient to a specialist
After the Part B deductible, the patient generally pays 20 percent of the Medicare-approved amount, although supplemental or other insurance may affect the final cost.
Why Early Evaluation Matters
An earlier diagnosis may allow a person to discuss medications that can slow disease progression for certain patients. These treatments do not cure Alzheimer’s disease and are not appropriate for everyone, but eligibility may depend on the type and stage of the disease.
Early evaluation also creates an opportunity to address safety, driving, medication management, financial vulnerability, housing, caregiving, and future long-term care needs.
For South Carolina families, this can be an especially important time to review estate planning documents. A plan may include:
A durable financial power of attorney
A South Carolina health care power of attorney
A living will
HIPAA authorizations
A will and/or trust
Up-to-date beneficiary designations
Instructions for managing finances and digital accounts
A plan for future care and caregiver responsibilities
An Alzheimer’s diagnosis does not automatically mean a person lacks legal capacity. Capacity is decision-specific and may remain intact during the early stages of cognitive decline. However, waiting too long can make it more difficult—or impossible—for the individual to sign or update important legal documents. If the individual later lacks the requisite capacity and no effective decision-making authority is already in place, court proceedings may then be necessary to appoint someone to make decisions.
Planning Gives Families More Choices
Blood testing is an evolving tool, not a complete answer. Medical results should be interpreted by qualified health care professionals, while legal and financial planning should be based on the individual’s wishes, capacity, family circumstances, assets, and anticipated care needs.
LawyerLisa helps South Carolina families prepare for aging, incapacity, dementia, caregiving, long-term care, and Medicaid eligibility. Seeking guidance while a loved one can still participate meaningfully in decisions may preserve autonomy and give the entire family more options.
Give us a call at 803.563.5163. We’re here to help and ready when you are.
For educational purposes only. This is not legal advice.
